The method is a special type of mass spectrometry which can be used on drugs ‘off the shelf’, i.e. without any radioactive labelling which may change the behaviour of the drug. With this method, researchers György Marko-Varga and Thomas Fehniger have managed to create a molecular image of the drug in the tissue.
The tissue examined comes from biopsies from the lungs of patients with lung cancer and chronic obstructive lung disease (COPD), who have inhaled a drug to dilate the airways. The examination showed the precise spatial distribution of the drug within the tissue. The results are based on an analysis of 3 000 measurement points of 0.01 mm2 in each biopsy sample.
“When you want to register a new drug, you must be able to both explain its exact mechanisms of action and show that it is effective and safe. In order to avoid side-effects, the drug should reach only the cells for which it is intended. Our new technical platform makes it easier to show this”, says György Marko-Varga.
He believes it will be possible to use the new technology to develop safer and more effective drug candidates. In the future it could also be used in clinical treatment, to help doctors select the right drug for a specific patient.
The researchers first conducted animal experiments, using drug doses 100 times higher than those now measured in patients. The group then optimised and refined the technology to achieve the sensitivity needed for measuring doses of drugs normally administered to patients.
Professors György Marko-Varga and Thomas Fehniger are both members of the Department of Measurement Technology and Industrial Electrical Engineering at Lund University. Thomas Fehniger (who is the principal author of the article) is currently working at The Tallinn University of Technology, sponsored by the Estonian Science Foundation under the European Social Fund, while György Marko-Varga works part time for the University of Tokyo. The two researchers have previously worked at the pharmaceuticals company AstraZeneca, which has also contributed to the study. The study was recently published in the journal Analytical Chemistry.
Thomas Fehniger | EurekAlert!
Newly discovered bacteria-binding protein in the intestine
08.12.2016 | University of Gothenburg
The balancing act: An enzyme that links endocytosis to membrane recycling
07.12.2016 | National Centre for Biological Sciences
In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.
Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...
Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...
A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.
Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...
In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.
“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...
The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.
The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...
16.11.2016 | Event News
01.11.2016 | Event News
14.10.2016 | Event News
08.12.2016 | Materials Sciences
08.12.2016 | Materials Sciences
08.12.2016 | Physics and Astronomy